Grading: 1C 4.2.5 In women commencing HAART in pregnancy liver function tests (LFTs) should be performed as per routine initiation of HAART and then at each antenatal visit. Grading: 1C 4.2.6 In the event that a woman who has initiated HAART during pregnancy has not achieved a plasma VL of

<50 HIV RNA copies/mL at 36 weeks the following interventions are recommended: Review adherence and concomitant medication. Perform resistance test if appropriate. Ribociclib chemical structure Consider therapeutic drug monitoring (TDM). Optimize to best regimen. Consider intensification. 5.1.1 It is recommended that women conceiving on an effective HAART regimen should continue this even if it contains efavirenz or does not contain zidovudine. Grading: 1C   Exceptions are:     (i) Protease inhibitor (PI) monotherapy should be intensified to include (depending on tolerability, resistance and previous antiretroviral (ARV) history) one or more agents that cross the placenta. Grading: 2D   (ii) The combination of stavudine and didanosine should not be prescribed in pregnancy. Grading: 1D 5.2.1 Women requiring ART for their own health should commence treatment as soon as possible as per BHIVA guidelines for the treatment

of HIV-1 positive adults with antiretroviral therapy 2012 (www.bhiva.org/PublishedandApproved.aspx). Grading: 1A 5.2.2 Although there is most evidence and experience in pregnancy with zidovudine plus lamivudine, tenofovir plus emtricitabine or abacavir plus lamivudine are acceptable nucleoside backbones. Grading: 2C 5.2.3 In the absence of specific contraindications, it is recommended Sotrastaurin manufacturer that the third agent in HAART should be efavirenz or nevirapine (if the CD4 cell count is <250 cells/μL) or a boosted PI. Grading: 1C 5.2.4 No routine dose alterations are recommended Leukocyte receptor tyrosine kinase for ARVs during pregnancy if used at adult licensed doses with the exception of darunavir, which should be dosed twice daily.

Grading: 1C   Consider third trimester TDM particularly if combining tenofovir and atazanavir. Grading: 1C   If dosing off licence consider switching to standard dosing throughout pregnancy or regular TDM. Grading: 1C 5.3.1 All women should have commenced ART by week 24 of pregnancy. Grading: 1C 5.3.2 Although there is most evidence and experience in pregnancy with zidovudine plus lamivudine, tenofovir plus emtricitabine or abacavir plus lamivudine are acceptable nucleoside backbones. Grading: 2C 5.3.3 In the absence of specific contraindications, it is recommended that HAART should be boosted-PI-based. The combination of zidovudine, lamivudine and abacavir can be used if the baseline VL is <100 000 HIV RNA copies/mL plasma. Grading: 1C 5.3.4 Zidovudine monotherapy can be used in women planning a caesarean section (CS) who have a baseline VL <10 000 HIV RNA copies/mL and CD4 cell count of >350 cells/μL. Grading: 1A 5.3.